Viemed Healthcare, Inc. (VMD) Market Cap & Valuation Ratios
Viemed Healthcare, Inc. (VMD) has a market cap of $373.3M, a trailing P/E of 27.2 and a price-to-sales ratio of 1.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VMDViemed Healthcare, Inc.Follow VMD — free
—
Price chart with a free account
- Market cap
- 373.3M
- P/E TTM
- 27.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| VMD | 0.4 | 27.2 | 1.2 | 7.0 | 7.8% | +25% | 8% | 12% |
| TCMD | 0.5 | 21.9 | 1.3 | 11.2 | 5.0% | +17% | 10% | 15% |
| RCEL | 0.5 | — | 6.8 | — | -5.3% | +1.0% | -47% | -263% |
| MASS | 0.5 | — | 6.1 | — | 0.1% | +13% | -64% | -52% |
| CERS | 0.5 | — | 1.9 | — | -0.4% | +23% | -0.6% | -1% |
| NPCE | 0.4 | — | 4.6 | — | -2.6% | +12% | -15% | -27% |
| OFIX | 0.4 | — | 0.6 | 37.9 | -7.0% | +3% | -5% | -7% |
| CV | 0.3 | — | 24.5 | — | -8.0% | +11% | -217% | -737% |
| QSI | 0.3 | — | 121.3 | — | — | -53% | — | -62% |
| CLPT | 0.3 | — | 7.1 | — | -11.2% | +26% | -73% | -160% |
| TMCI | 0.3 | — | 1.4 | — | -9.0% | -4% | -26% | -42% |
| Median of these 10 | 21.9 | 5.3 | 24.5 | -5.3% | +11% | -26% | -47% |
P/E 27.2 vs. a peer median of 21.9; EV/Sales 1.2 vs. 5.3. VMD's own P/E sits at the 47th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesViemed Healthcare, Inc. — questions
- What is Viemed Healthcare, Inc.'s market cap?
- $373.3M.
- What is Viemed Healthcare, Inc.'s P/E ratio?
- 27.2 on trailing twelve-month earnings to 2026-06-30.
- What is Viemed Healthcare, Inc.'s price-to-sales ratio?
- 1.2.
Every figure on this page comes from Viemed Healthcare, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.